Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ichiro Hanamura

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Cell Death Discovery|May 26, 2021
CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemiaSivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, et al.
Blood|May 27, 2006
The molecular classification of multiple myelomaFenghuang Zhan, Yongsheng Huang, Simona Colla, et al.
Cancer Cell|April 18, 2006
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patientsDaniel R Carrasco, Giovanni Tonon, Yongsheng Huang, et al.
Leukemia Research|November 12, 2013
Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myelomaAtsushi Inagaki, Emi Tajima, Miyuki Uranishi, et al.
British Journal of Haematology|July 28, 2021
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survivalTakeshi Yamashita, Hiroyuki Takamatsu, Koji Kawamura, et al.
Haematologica|July 20, 2023
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugsHiroyuki Takamatsu, Tomohiro Matsuda, Shohei Mizuno, et al.
International Journal of Clinical Oncology|March 17, 2024
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2Yoshinori Kikuchi, Hideaki Shimada, Fumiyuki Yamasaki, et al.
British Journal of Haematology|June 26, 2020
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
International Journal of Hematology|May 17, 2021
Expression of activated integrin β7 in multiple myeloma patientsNaoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Cell Death Discovery|May 26, 2021
CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemiaSivasundaram Karnan, Ichiro Hanamura, Akinobu Ota, et al.
Blood|May 27, 2006
The molecular classification of multiple myelomaFenghuang Zhan, Yongsheng Huang, Simona Colla, et al.
Cancer Cell|April 18, 2006
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patientsDaniel R Carrasco, Giovanni Tonon, Yongsheng Huang, et al.
Leukemia Research|November 12, 2013
Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myelomaAtsushi Inagaki, Emi Tajima, Miyuki Uranishi, et al.
British Journal of Haematology|July 28, 2021
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survivalTakeshi Yamashita, Hiroyuki Takamatsu, Koji Kawamura, et al.
Haematologica|July 20, 2023
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugsHiroyuki Takamatsu, Tomohiro Matsuda, Shohei Mizuno, et al.
International Journal of Clinical Oncology|March 17, 2024
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2Yoshinori Kikuchi, Hideaki Shimada, Fumiyuki Yamasaki, et al.
British Journal of Haematology|June 26, 2020
Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
International Journal of Hematology|May 17, 2021
Expression of activated integrin β7 in multiple myeloma patientsNaoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, et al.
Pageof 9